Drugs / EVE-Treg
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06991361 | May 2026 → Dec 2028 expected | chronic graft versus host disease | Leslie Kean | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVE-Treg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06991361 ↗ |
| Modality | Cell therapy | “Ex Vivo-Expanded (EVE) Regulatory T cells.” NCT06991361 ↗ |